Contact
searchSearch
HMP Global
Login

Hepatocellular Carcinoma

Hepatocellular Carcinoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Arndt Vogel, MD
Videos
Biomarker-Guided Therapy May Improve Treatment Selection in Hepatocellular Carcinoma
07/22/2026
Arndt Vogel, MD
Arndt Vogel, MD, discusses results from the phase 2 IMMUNIB trial showing that first-line lenvatinib plus nivolumab demonstrated encouraging clinical activity in unresectable hepatocellular carcinoma while exploratory biomarker analyses...
Arndt Vogel, MD, discusses results from the phase 2 IMMUNIB trial showing that first-line lenvatinib plus nivolumab demonstrated encouraging clinical activity in unresectable hepatocellular carcinoma while exploratory biomarker analyses...
Arndt Vogel, MD, discusses...
07/22/2026
Oncology
Ghassan Abou-Alfa, MD, PhD
Videos
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
06/18/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
06/18/2026
Oncology
Catherine Wilbur, MD
Videos
Baseline Cytokines May Predict Response to Immunotherapy and Anti-VEGF Therapy in Advanced Hepatocellular Carcinoma
03/09/2026
Catherine Wilbur, MD
Catherine Wilbur, MD, discusses a translational study showing that baseline and dynamic cytokine profiles were associated with outcomes in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors with or...
Catherine Wilbur, MD, discusses a translational study showing that baseline and dynamic cytokine profiles were associated with outcomes in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors with or...
Catherine Wilbur, MD, discusses...
03/09/2026
Oncology
Richard Finn, MD
Videos
REFINE Supports the Real-World Safety and Effectiveness of Regorafenib in Advanced Hepatocellular Carcinoma
03/02/2026
Richard Finn, MD
Richard Finn, MD, discusses findings from the prospective REFINE study showing that regorafenib maintained a favorable safety profile and clinical effectiveness in patients with advanced hepatocellular carcinoma, supporting its continued role...
Richard Finn, MD, discusses findings from the prospective REFINE study showing that regorafenib maintained a favorable safety profile and clinical effectiveness in patients with advanced hepatocellular carcinoma, supporting its continued role...
Richard Finn, MD, discusses...
03/02/2026
Oncology
Stephen Lam Chan, MD
Videos
Adjuvant Pembrolizumab Fails to Improve Recurrence-Free Survival in Hepatocellular Carcinoma
01/26/2026
Stephen Lam Chan, MD
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial showing that adjuvant pembrolizumab did not improve recurrence-free survival following curative-intent surgery or local ablation for hepatocellular carcinoma,...
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial showing that adjuvant pembrolizumab did not improve recurrence-free survival following curative-intent surgery or local ablation for hepatocellular carcinoma,...
Stephen Lam Chan, MD, discusses...
01/26/2026
Oncology
Farshid Dayyani, MD, PhD
Videos
Combination Immunotherapy and TACE Demonstrate Encouraging Activity in Liver-Limited Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses results from a phase 2 trial showing that combination immunotherapy, targeted therapy, and transarterial chemoembolization achieved encouraging response rates and enabled curative-intent resection in...
Farshid Dayyani, MD, PhD, discusses results from a phase 2 trial showing that combination immunotherapy, targeted therapy, and transarterial chemoembolization achieved encouraging response rates and enabled curative-intent resection in...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Farshid Dayyani, MD, PhD
Videos
Immunotherapy, TACE, and Cabozantinib in Unresectable Hepatocellular Carcinoma
01/14/2026
Farshid Dayyani, MD, PhD
Farshid Dayyani, MD, PhD, discusses a phase 2 study evaluating induction ipilimumab plus nivolumab followed by transarterial chemoembolization and consolidation with cabozantinib plus nivolumab in patients with unresectable hepatocellular...
Farshid Dayyani, MD, PhD, discusses a phase 2 study evaluating induction ipilimumab plus nivolumab followed by transarterial chemoembolization and consolidation with cabozantinib plus nivolumab in patients with unresectable hepatocellular...
Farshid Dayyani, MD, PhD,...
01/14/2026
Oncology
Nadine Abi-Jaoudeh, MD
Videos
TATE Plus Nivolumab Demonstrates Activity in Immunotherapy-Refractory Hepatocellular Carcinoma
01/13/2026
Nadine Abi-Jaoudeh, MD
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 trial showing that transarterial tirapazamine embolization combined with nivolumab produced encouraging and durable responses in patients with immunotherapy-refractory advanced...
Nadine Abi-Jaoudeh, MD, discusses results from a phase 2 trial showing that transarterial tirapazamine embolization combined with nivolumab produced encouraging and durable responses in patients with immunotherapy-refractory advanced...
Nadine Abi-Jaoudeh, MD,...
01/13/2026
Oncology
Olatunji Alese, MD, Winship Cancer Center
Videos
Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma
09/17/2025
O. Alese
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses the use of dual immune checkpoint blockade, for frontline therapy and sequencing, for patients with advanced hepatocellular carcinoma.
Olatunji Alese, MD, discusses...
09/17/2025
Oncology
Ruth He, MD
Videos
Frontline Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma
04/15/2025
Aiwu Ruth He, MD, PhD
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses...
04/15/2025
Oncology

Recent News

News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use